WO2012170614A3 - Dna methylation markers in non-small cell lung cancer and methods of using the same - Google Patents

Dna methylation markers in non-small cell lung cancer and methods of using the same Download PDF

Info

Publication number
WO2012170614A3
WO2012170614A3 PCT/US2012/041228 US2012041228W WO2012170614A3 WO 2012170614 A3 WO2012170614 A3 WO 2012170614A3 US 2012041228 W US2012041228 W US 2012041228W WO 2012170614 A3 WO2012170614 A3 WO 2012170614A3
Authority
WO
WIPO (PCT)
Prior art keywords
lung cancer
small cell
cell lung
methods
same
Prior art date
Application number
PCT/US2012/041228
Other languages
French (fr)
Other versions
WO2012170614A2 (en
Inventor
Steven H. LIN
John Heymach
Jing Wang
John Minna
Luc Girard
Original Assignee
Board Of Regents, The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Regents, The University Of Texas System filed Critical Board Of Regents, The University Of Texas System
Publication of WO2012170614A2 publication Critical patent/WO2012170614A2/en
Publication of WO2012170614A3 publication Critical patent/WO2012170614A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers

Abstract

Provided herein are unique sets of genes that are regulated by methylation in non-small cell lung cancer ("NSCLC") that are useful as a biomarker or in an assay for determining, diagnosing or subtyping lung cancer and/or the outcome of certain drug therapies.
PCT/US2012/041228 2011-06-07 2012-06-07 Dna methylation markers in non-small cell lung cancer and methods of using the same WO2012170614A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161494142P 2011-06-07 2011-06-07
US61/494,142 2011-06-07

Publications (2)

Publication Number Publication Date
WO2012170614A2 WO2012170614A2 (en) 2012-12-13
WO2012170614A3 true WO2012170614A3 (en) 2013-04-04

Family

ID=47296727

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/041228 WO2012170614A2 (en) 2011-06-07 2012-06-07 Dna methylation markers in non-small cell lung cancer and methods of using the same

Country Status (1)

Country Link
WO (1) WO2012170614A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140227694A1 (en) * 2013-02-08 2014-08-14 Zymo Research Corporation Epigenetic markers of pluripotency
CA2926215A1 (en) * 2013-10-06 2015-04-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modified pseudomonas exotoxin a
CN108680745B (en) * 2018-01-03 2021-06-15 湖州市中心医院 Application method of serum lipid biomarker in early diagnosis of NSCLC
CN115772565B (en) * 2021-09-08 2023-09-05 广州市基准医疗有限责任公司 Methylation site for auxiliary detection of lung cancer somatic EGFR gene mutation and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080241842A1 (en) * 2005-07-09 2008-10-02 Lovelace Respiratory Research Institute Gene Methylation as a Biomarker in Sputum
WO2009023172A2 (en) * 2007-08-09 2009-02-19 The Johns Hopkins University Predictions of responsiveness to egfr inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080241842A1 (en) * 2005-07-09 2008-10-02 Lovelace Respiratory Research Institute Gene Methylation as a Biomarker in Sputum
WO2009023172A2 (en) * 2007-08-09 2009-02-19 The Johns Hopkins University Predictions of responsiveness to egfr inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GOTO, Y. ET AL.: "Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma", CANCER RES., vol. 69, no. 23, 1 December 2009 (2009-12-01), pages 9073 - 9082 *
GU, J. ET AL.: "Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer", CLIN. CANCER RES., vol. 12, no. 24, 15 December 2006 (2006-12-15), pages 7329 - 38 *
KIM, B. ET AL.: "Clinical validity of the lung cancer biomarkers identified by bioinformatics analysis of public expression data", CANCER RES., vol. 67, no. 15, 1 August 2007 (2007-08-01), pages 7431 - 7438 *

Also Published As

Publication number Publication date
WO2012170614A2 (en) 2012-12-13

Similar Documents

Publication Publication Date Title
WO2009075799A3 (en) Method for diagnosing lung cancers using gene expression profiles in peripheral blood mononuclear cells
WO2013006495A3 (en) Methods of predicting prognosis in cancer
IL210026A (en) Non-small cell lung cancer detection marker, detection method thereof, related reagent kit and biochip
WO2012153187A3 (en) Markers for cancer prognosis and therapy and methods of use
WO2012006447A3 (en) Gene signatures for cancer prognosis
WO2010030365A3 (en) Thyroid tumors identified
WO2013166186A8 (en) Method for determining complete response to anticancer therapy
WO2011112845A3 (en) Methods and compositions related to a multi-methylation assay to predict patient outcome
WO2010045318A3 (en) Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
EP2611941A4 (en) Gene signatures for cancer diagnosis and prognosis
CA2840149C (en) Methods and nucleic acids for determining the prognosis of a cancer subject
WO2012119113A3 (en) Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures
WO2011087709A3 (en) Eml4-alk translocations in lung cancer
EP2198021A4 (en) Ebi3, dlx5, nptx1 and cdkn3 for target genes of lung cancer therapy and diagnosis
WO2012138783A3 (en) Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
WO2011153545A3 (en) Gene expression signature as a predictor of chemotherapeutic response in breast cancer
WO2011100749A3 (en) Methods and materials for detecting viral or microbial infections
WO2010051314A3 (en) Genomic classification of non-small cell lung carcinoma based on patterns of gene copy number alterations
WO2012061510A3 (en) Methods of predicting cancer cell response to therapeutic agents
WO2012135841A3 (en) Emt signatures and predictive markers and method of using the same
WO2011097509A3 (en) Hypoxia-related gene signatures for cancer classification
EP2744919A4 (en) Gene signatures for lung cancer prognosis and therapy selection
WO2013083098A3 (en) Method of determination of cancer cell drug sensitivity towards aurora kinase inhibitors
WO2014008312A3 (en) Primers, assays and methods for detecting an e. coli subtype
NZ701652A (en) Breast cancer prognosis, prediction of progesterone receptor subtype and|prediction of response to antiprogestin treatment based on gene expression

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12797639

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12797639

Country of ref document: EP

Kind code of ref document: A2